<DOC>
	<DOC>NCT02089828</DOC>
	<brief_summary>To compare the efficacy and cost-effectiveness between purified CD34+ cells and peripheral blood mononuclear cells in treatment of critical limb ischemia</brief_summary>
	<brief_title>Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Thromboangiitis Obliterans</mesh_term>
	<criteria>Rutherford scale of 45 thromboangiitis obliterans, peripheral arterial disease, or arteritis caused by other etiologies, such as collagen diseases surgical or endovascular procedures are considered unlikely to have successful longterm revascularization, or have failed more than 4 weeks of critical limb ischemia if present, a nonhealing ulcer after more than 4 weeks of optimal care by a wound care physician and a nurse within 3 months of an acute myocardial infarction any contraindication for the administration of granulocyte colony stimulating factor (GCSF)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>